Literature DB >> 7570716

Synthesis of C-6 fluoroandrogens: evaluation of ligands for tumor receptor imaging.

Y S Choe1, J A Katzenellenbogen.   

Abstract

Seven androgens, substituted with fluorine at C-6, were prepared as potential imaging agents for androgen receptor-positive prostate tumors and were evaluated in vitro in terms of their lipophilicity and their relative binding affinities (RBA, relative to R 1881 = 100) for the androgen receptor and for sex steroid binding protein. Introduction of a fluorine atom into the C-6 position of an androgen generally decreases binding affinity to the androgen receptor, except in the two cases: 6 alpha-fluoro-19-nor-testosterone (RBA = 41.6 versus 30.6 for the unsubstituted steroid) and 6 alpha-fluorotestosterone (RBA = 8.9 versus 6.6). Receptor binding of the C-6 fluoro-androgens is also stereospecific, showing higher binding affinities for the alpha-epimers compared to the corresponding beta-epimers (4:1-15:1). Binding affinity to sex steroid binding protein is the lowest with 19-nor-testosterone, which is also the least lipophilic androgen studied. Based on the binding properties of compounds in this series, 6 alpha-fluoro-19-nor-testosterone appears to have the most promise as a tumor imaging agent.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7570716     DOI: 10.1016/0039-128x(95)00009-f

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  2 in total

1.  Bioactive Rearrangement Products from Aqueous Photolysis of Pharmaceutical Steroids.

Authors:  Nicholas C Pflug; Christopher J Knutson; Dalma Martinović-Weigelt; Dale C Swenson; Kristine H Wammer; David M Cwiertny; James B Gloer
Journal:  Org Lett       Date:  2019-04-25       Impact factor: 6.005

Review 2.  PET Imaging Agents (FES, FFNP, and FDHT) for Estrogen, Androgen, and Progesterone Receptors to Improve Management of Breast and Prostate Cancers by Functional Imaging.

Authors:  John A Katzenellenbogen
Journal:  Cancers (Basel)       Date:  2020-07-23       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.